SCHEMBL202780

SCHEMBL202780

COC(=O)C1CC(=O)CN1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 2/20 0.48
HSD17B10 Q99714 2/20 0.48
CYP1A2 P05177 1/20 0.48
GAA P10253 1/20 0.48
CYP2D6 P10635 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
CYP2C19 P33261 1/20 0.48
KMT2A Q03164 1/20 0.41
BRD4 O60885 1/20 0.38
MMP2 P08253 1/20 0.38
ANPEP P15144 1/20 0.38
BACE1 P56817 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33
CHRNB2 P17787 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202781 1.00 ALDH1A1 (0.48) ALDH1A1KDM4EHSD17B10CYP1A2GAA
Trifluoroacetic Acid SCHEMBL19064805 0.88 CYP1A2 (0.41) ALDH1A1KDM4EHSD17B10CYP1A2GAA
SCHEMBL29308741 0.83 KDM4E (0.41) ALDH1A1KDM4EHSD17B10CYP1A2GAA
SCHEMBL23046207 0.81 ALDH1A1 (0.39) ALDH1A1KDM4EHSD17B10CYP1A2GAA
SCHEMBL447421 0.81 ALDH1A1 (0.39) ALDH1A1KDM4EHSD17B10CYP1A2GAA
SCHEMBL16774517 0.81 MAPK1 (0.39) ALDH1A1KDM4EHSD17B10CYP1A2GAA
SCHEMBL15173804 0.81 CYP1A2 (0.39) ALDH1A1KDM4EHSD17B10CYP1A2GAA
SCHEMBL16774516 0.81 MAPK1 (0.39) ALDH1A1KDM4EHSD17B10CYP1A2GAA
SCHEMBL21271467 0.81 CYP1A2 (0.39) ALDH1A1KDM4EHSD17B10CYP1A2GAA
Hydrochloric Acid SCHEMBL28021123 0.79 KDM4E (0.33) ALDH1A1KDM4EHSD17B10CYP1A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024165071-A1 IMINE COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 上海葆正医药科技有限公司 2024-08-15 WO disclosed
CN-118085014-A Preparation method of minoxidil 和德化学(苏州)有限公司 2024-05-28 CN disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
US-11692043-B2 Peptidomimetic compounds and antibody-drug conjugates thereof MEDIMMUNE LIMITED (GB) 2023-07-04 US disclosed
US-20220298161-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF SPIROGEN SARL (CH) 2022-09-22 US disclosed
US-11135303-B2 Pyrrolobenzodiazepines and conjugates thereof MEDIMMUNE LIMITED (GB) 2021-10-05 US disclosed
EP-3082872-B1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF GENENTECH INC (US) 2020-12-09 EP disclosed
US-20200157240-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF MEDIMMUNE LIMITED (GB) 2020-05-21 US disclosed
EP-2800738-B1 HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE NOVARTIS AG (CH) 2020-04-08 EP disclosed
CN-107011229-B The application method of heterocyclic compound and they 诺华股份有限公司 2019-11-05 CN disclosed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
WO-2011130598-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF SPIROGEN LIMITED (GB) 2011-10-20 WO disclosed
US-20110256157-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF SPIROGEN LIMITED (GB) 2011-10-20 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157240-A1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF DNPEP, LNPEP, VIP ALDH1A1 3063/4885KDM4E 3775/4885HSD17B10 4273/4885
US-20110256157-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF HDAC10, PBDC1, PDCD10 ALDH1A1 1192/4885KDM4E 2183/4885HSD17B10 853/4885
US-11135303-B2 Pyrrolobenzodiazepines and conjugates thereof CD79B, BCL6B, DRD1 ALDH1A1 1055/4885KDM4E 3620/4885HSD17B10 2933/4885
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 ALDH1A1 343/4885KDM4E 2101/4885HSD17B10 111/4885
US-11692043-B2 Peptidomimetic compounds and antibody-drug conjugates thereof DNPEP, LNPEP, VIP ALDH1A1 3063/4885KDM4E 3775/4885HSD17B10 4273/4885
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE ALDH1A1 2309/4885KDM4E 2323/4885HSD17B10 585/4885
US-20220298161-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF HDAC10, PBDC1, PDCD10 ALDH1A1 1192/4885KDM4E 2183/4885HSD17B10 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.